Journal Article

Viral Dynamic Surveillance in COVID-19 Patients: A Cohort Study

Pang, XiaoFeng, Cao, LiangLi, Zhao, FeiJun, Xie, ZhouHua, Wei, ShanQiu, Luo, XiaoCheng, Liang, JuanYing, Zang, Ning, Su, HanZhen, Tang, XiKe, Wang, YuanLi, Zhou, JinAi, Bi, DeWu, Lin, YanRong, Qin, YaQin, Xi, ShaoYong, Lan, ZhenXu, Ma, QiuYing, Mo, LiDa, Lin, Lü, Chen, ZhenCheng, Luo, XiaoLu, Liu, ZeDuan

2022

Overview

Background. Coronavirus disease 2019 (COVID-19) is a potentially fatal pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially those of novel SARS-CoV-2 variants and infection has affected over 700 million people globally. Methods. This retrospective, descriptive study included 118 patients admitted with SARS-CoV-2 infection as confirmed by real-time reverse transcription polymerase chain reaction. Results. The median duration of detectable SARS-CoV-2 infection in patients with high ALT, AST, and PLT/LYMPH, or low CD4+, CD8+, and PLT/MONO was considerably longer. In the risk factor model, multivariate analysis was performed for the estimation of ALT (HR, 0.54; 95% CI, 0.36-0.81), AST (HR, 0.56; 95% CI, 0.34-0.93), CD4+ (HR,0.77; 95% CI, 0.48-1.24), CD8+ (HR,0.64; 95% CI, 0.37-1.11), PLT/LYMPH (HR, 1.16; 95% CI, 0.76-1.77), and PLT/MONO (HR, 0.64; 95% CI, 0.43-0.94). Conclusions. The longer viral RNA duration was associated with a higher International Prognostic Index score (p=0.0013), demonstrating for the first time that multivariate features of the bioindicators closely associated with SARS-CoV-2-infected patients clear the virus.

• Publisher: Hindawi,John Wiley & Sons, Inc
• Subject: Analysis / Bioindicators / CD4 antigen / CD8 antigen / Cohort analysis / Coronaviruses / COVID-19 / Disease transmission / Electronic health records / Enzymes / Hospitals / Indicator species / Infections / Laboratories / Lymph / Medical records / Methods / Multivariate analysis / Mutation / Polymerase chain reaction / Respiratory diseases / Reverse transcription / Risk analysis / Risk factors / RNA / Severe acute respiratory syndrome / Severe acute respiratory syndrome coronavirus 2 / Survival analysis / Viral diseases / Viruses